Last updated: February 14, 2026
What Is the Drug NDC 50419-0459?
NDC 50419-0459 refers to Sebelipase alfa (Kanuma), an enzyme replacement therapy for lipid storage disorders, specifically lysosomal acid lipase deficiency (LAL-D). Approved by the FDA in 2015, Kanuma targets a rare genetic disorder with a small patient population.
Market Size and Patient Population
The patient population for LAL-D is estimated at fewer than 1,000 individuals globally, with higher prevalence in regions with established genetic screening.
- United States: Approximately 300-500 cases.
- Europe and other regions: Similar or smaller numbers, with under 1,000 total cases.
Competitive Landscape
Sebelipase alfa is currently the sole approved drug for LAL-D. The market's competitiveness depends on:
- The rarity of the condition.
- The exclusivity provided by orphan drug designation.
- The potential for biosimilar or alternative therapies entering the space, which remains unlikely in the short term due to high development and regulatory barriers.
Pricing of NDC 50419-0459
Pricing in the US typically reflects orphan drug premiums, limited competition, and the high cost of enzyme replacement therapies.
- Current list price: Approximately $365,000 to $385,000 per year per patient.
- Price factors:
- Treatment involves biweekly infusions.
- Cost includes drug acquisition, administration, and monitoring.
- Reimbursement strategies, including Medicare, Medicaid, and private insurers, often negotiate discounts.
Market Dynamics and Growth Projections
Given the ultra-rare status, the market size is limited but potentially stable due to:
- No current therapeutic alternatives.
- Increasing diagnostic rates raising diagnosed patient numbers.
The estimated global market value for Sebelipase alfa is approximately $100 million to $150 million in 2023, with a compound annual growth rate (CAGR) of about 4% to 6% driven by diagnostic expansion and increased awareness.
Future Price and Market Trends
- Pricing trajectory: Stable or slight increases aligned with inflation and healthcare cost trends.
- Potential for biosimilar entry: Low in the next 5-10 years owing to regulatory complexity and the rarity of the condition.
- Market expansion: Limited; growth relies primarily on increased diagnosis rather than new patient populations.
Regulatory and Reimbursement Outlook
- Continued support through orphan drug incentives.
- Increasing emphasis on value-based pricing.
- Potential for negotiations to reduce net prices over time due to healthcare cost containment efforts.
Key Takeaways
- NDC 50419-0459 (Sebelipase alfa) is a rare disease enzyme replacement therapy with a small but stable market.
- The global market is valued at approximately $100-$150 million, with annual treatment costs around $365,000–$385,000 per patient.
- Growth depends heavily on diagnostic expansion rather than an increasing patient base.
- Price stability is likely given its orphan status and lack of competitors.
- Future market risk factors include regulatory hurdles for biosimilars and healthcare cost pressures.
FAQs
1. What is the primary indication for NDC 50419-0459?
Lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder affecting lipid metabolism.
2. How does the price of Sebelipase alfa compare with other enzyme replacement therapies?
It is similar, typically falling within the $350,000–$400,000 range annually, reflecting comparable orphan drug premiums.
3. Are there any upcoming biosimilar versions of Sebelipase alfa?
No biosimilars are currently at advanced development stages due to the complexities and high costs associated with biosimilar entry for enzyme therapies.
4. What factors could influence future pricing?
Healthcare policy changes, reimbursement negotiations, or new evidence on clinical value could impact net prices.
5. How does patient diagnosis rate affect market projections?
Diagnostic improvements can increase the treated population, potentially expanding the market modestly despite the rarity.
References
- FDA Drug Approval Package: Sebelipase alfa [1].
- IQVIA (2023): Enzyme replacement therapy market data.
- Orphan Drug Designation Reports [2].
- Genetic and Epidemiological Studies on LAL-D [3].
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125532Orig1s000MedR.pdf
[2] https://www.orphandrugalliance.org/
[3] https://pubmed.ncbi.nlm.nih.gov/
